Stevanato (STVN) delivered robust financial performance in Q4 2025, posting revenue of €218 million and adjusted EBITDA of €54 million, driven by sustained demand in biologics packaging. The company reaffirmed its full-year 2026 guidance, signaling continued confidence in its growth trajectory.
- Q4 2025 revenue: €218 million, up 7% YoY
- Adjusted EBITDA: €54 million, +10% YoY
- Full-year 2026 revenue guidance: €880M–€900M
- Adjusted EBITDA margin target: 24%–26%
- €50 million capital investment allocated to facility upgrades and R&D
- Stevanato’s core focus: biologics and high-value injectable packaging
Stevanato Group (STVN) reported fourth-quarter 2025 revenue of €218 million, a 7% year-over-year increase, reflecting strong execution across its global manufacturing network. The company achieved an adjusted EBITDA of €54 million, representing a 10% improvement from the same period in 2024, underpinned by operational efficiency and favorable product mix in the pharmaceutical packaging segment. The results were supported by growing demand for specialty packaging solutions, particularly for biologics and high-value injectable therapies. Stevanato’s core business in primary packaging for parenteral drugs continued to expand, with new contracts secured in North America and Europe. The company emphasized that its strategic investments in automation and digitalization have enhanced production capacity and reduced lead times. Stevanato maintained its full-year 2026 revenue guidance of €880 million to €900 million, with adjusted EBITDA margins expected to remain in the 24% to 26% range. The company also confirmed its capital allocation strategy, including a €50 million investment in facility upgrades and R&D for next-generation containment systems. Market reaction was muted, with STVN shares trading flat on the day. However, analysts noted that the results reinforce the company’s position as a key supplier in the pharmaceutical supply chain, particularly amid rising demand for stable, high-precision packaging solutions. The broader healthcare and industrial sectors showed modest movement, with the VIX (CL=F) and broader equity indices (VIX) indicating stable risk appetite.